Related Experiment Videos
Verner-Morrison syndrome and vasoactive intestinal polypeptide (VIP)
Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1979
Summary
Verner-Morrison syndrome, a rare condition, requires clearer definition, particularly regarding vasoactive intestinal peptide (VIP). A presented case shows a strong link between disease activity and circulating VIP levels.
Area of Science:
- Endocrinology
- Gastroenterology
- Oncology
Background:
- Verner-Morrison syndrome is a rare clinical entity with debated diagnostic criteria.
- The role of vasoactive intestinal peptide (VIP) in the syndrome's pathophysiology remains incompletely understood.
- The clinical utility of measuring VIP levels for disease monitoring is not well-established.
Purpose of the Study:
- To survey the clinical features of Verner-Morrison syndrome.
- To clarify the role of VIP in the syndrome.
- To assess the clinical value of VIP measurements.
Main Methods:
- Literature review of clinical features.
- Case study presentation.
- Correlation analysis of disease activity and circulating VIP levels.
Main Results:
- The clinical presentation of Verner-Morrison syndrome is diverse and requires further definition.
- A case demonstrated a significant correlation between disease activity and circulating VIP levels.
- VIP measurements may hold clinical value in assessing disease status.
Conclusions:
- Verner-Morrison syndrome necessitates a more precise definition.
- VIP plays a crucial role in the syndrome's manifestation.
- Circulating VIP levels can serve as a valuable biomarker for disease activity.